Efficacy and Safety of Perlane-L in the Correction of Midface Volume Deficit
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States
-
San Francisco, California, United States
-
Vista, California, United States
-
-
Florida
-
Aventura, Florida, United States
-
Coral Gables, Florida, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Maryland
-
Hunt Valley, Maryland, United States
-
-
Massachusetts
-
Chestnut Hill, Massachusetts, United States
-
-
New York
-
Mount Kisco, New York, United States
-
New York, New York, United States
-
-
Oregon
-
Eugene, Oregon, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Loss of Fullness in Midface Area
- Other items as identified in the protocol
Exclusion Criteria:
- History of allergy or hypersensitivity to injectable hyaluronic acid gel or lidocaine.
- Other items as identified in the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Perlane-L
Perlane-L treatment
|
Perlane-L Injection in the midface
|
|
Sham Comparator: Non-Treatment
Non-Treatment Arm
|
Non-treatment Arm
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Facial fullness using midface scale
Time Frame: Week 8
|
Change in facial fullness using midface scale.
|
Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Facial fullness using the midface scale
Time Frame: Up to 12-months post treatment
|
Change in facial fullness using midface scale.
|
Up to 12-months post treatment
|
|
Subject satisfaction using the GAIS
Time Frame: Up to 12-months post treatment
|
Compare treatment satisfaction as compared to no treatment, on the Global Aesthetic Improvement Scale (GAIS)
|
Up to 12-months post treatment
|
|
Aesthetic improvement
Time Frame: Up to 12-months post treatment
|
A subjective assessment of aesthetic improvement post baseline
|
Up to 12-months post treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- MA-1400-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.